Literature DB >> 11551835

Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats.

T Ohishi1, H Saito, K Tsusaka, K Toda, H Inagaki, Y Hamada, N Kumagai, K Atsukawa, H Ishii.   

Abstract

The tissue renin-angiotensin system has recently been demonstrated to reduce fibrogenesis in various organs. However, little has been clarified regarding its role in hepatic fibrosis. The purpose of this study was to investigate the effect of angiotensin-converting enzyme inhibitors on liver fibrogenesis induced in rats by low-dose chronic carbon tetrachloride administration. We used lisinopril that is absorbed in its active form and not metabolized in the liver to avoid any influence by the administration of the chemical. Carbon tetrachloride was administered twice a week i.p. Twelve and 24 weeks after the start of treatment, expanded periportal fibrosis or portal-portal bridgings and severe fat deposition were observed in the rats treated with carbon tetrachloride alone, and these findings were significantly reduced with the simultaneous treatment with lisinopril. The hydroxyproline content of the liver was significantly lower in the lisinopril-treated group. Angiotensin II up-regulated mRNA of pro alpha (I) collagen and transforming growth factor-beta in isolated hepatic stellate cells. These results suggest that the local tissue renin-angiotensin system plays a role in rat hepatic fibrogenesis induced by chronic carbon tetrachloride administration and that hepatic fibrogenesis is significantly reduced by ACE inhibitors.

Entities:  

Year:  2001        PMID: 11551835     DOI: 10.1016/s1386-6346(01)00102-4

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  17 in total

1.  Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.

Authors:  Joel Z Stengel; Stephen A Harrison
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-06

2.  Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation.

Authors:  Syeda H Afroze; Md Kamruzzaman Munshi; Allyson K Martínez; Mohammad Uddin; Maté Gergely; Claudia Szynkarski; Micheleine Guerrier; Damir Nizamutdinov; David Dostal; Shannon Glaser
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-02-12       Impact factor: 4.052

3.  Effect of angiotensin-converting enzyme inhibition on experimental hepatic fibrogenesis.

Authors:  Cansel Türkay; Ozlem Yönem; Sema Arici; Ayhan Koyuncu; Mehmet Kanbay
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

4.  Comprehensive characterization of serum clinical chemistry parameters and the identification of urinary superoxide dismutase in a carbon tetrachloride-induced model of hepatic fibrosis in the female Hanover Wistar rat.

Authors:  Rosemary Smyth; Michael R Munday; Malcolm J York; Christopher J Clarke; Theo Dare; John A Turton
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

5.  An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells.

Authors:  Nobuya Kurikawa; Miwa Suga; Shoko Kuroda; Keisuke Yamada; Hirokazu Ishikawa
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

6.  Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats.

Authors:  Yongzhong Wei; Suzanne E Clark; E Matthew Morris; John P Thyfault; Grace M E Uptergrove; Adam T Whaley-Connell; Carlos M Ferrario; James R Sowers; Jamal A Ibdah
Journal:  J Hepatol       Date:  2008-04-22       Impact factor: 25.083

7.  Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice.

Authors:  Christoph H Osterreicher; Kojiro Taura; Samuele De Minicis; Ekihiro Seki; Melitta Penz-Osterreicher; Yuzo Kodama; Johannes Kluwe; Manfred Schuster; Gavin Y Oudit; Josef M Penninger; David A Brenner
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

Review 8.  New treatments for nonalcoholic fatty liver disease.

Authors:  Stephen A Harrison
Journal:  Curr Gastroenterol Rep       Date:  2006-02

9.  Effects of enalaprilat on acute necrotizing pancreatitis in rats.

Authors:  Serdar Turkyilmaz; Etem Alhan; Cengiz Ercin; Birgul Kural Vanizor
Journal:  Inflammation       Date:  2007-07-25       Impact factor: 4.092

10.  Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.

Authors:  Phunchai Charatcharoenwitthaya; Jayant A Talwalkar; Paul Angulo; Andrea A Gossard; Jill C Keach; Janice L Petz; Roberta A Jorgensen; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2009-03-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.